Angiotensin II type 1 receptor / L-type calcium channel (dual)

Class

Fixed-dose combination (ARB + calcium channel blocker) -- low-dose telmisartan + amlodipine

This mechanism combines two complementary blood-pressure-lowering actions in a single fixed-dose formulation. The first component blocks the angiotensin II type 1 (AT1) receptor, a G-protein-coupled receptor that mediates the vasoconstrictive, sodium-retaining, and aldosterone-stimulating effects of the hormone angiotensin II within the renin-angiotensin-aldosterone system. The second component blocks L-type calcium channels on vascular smooth muscle and cardiac cells, reducing calcium influx that would otherwise drive muscle contraction, thereby relaxing arterial walls. Angiotensin receptor blockade addresses the hormonal and fluid-volume drivers of elevated pressure, while calcium channel blockade acts directly on vascular tone; because they act through distinct pathways, their effects are additive rather than redundant. Combining low doses of each drug can achieve blood pressure control comparable to a higher dose of either agent alone, while potentially reducing the incidence of dose-dependent side effects such as ankle swelling from calcium channel blockade or reflex effects from single-agent use. This dual mechanism is broadly relevant to essential hypertension and related cardiovascular risk reduction, particularly in patients whose blood pressure is not adequately controlled by a single antihypertensive class, where combination therapy is a standard strategy for achieving target blood pressure with better tolerability.